Cargando…

Decreased Expression of Urinary Mammalian Target of Rapamycin mRNA Is Related to Chronic Renal Fibrosis in IgAN

BACKGROUND: Renal fibrosis is a common outcome of all pathological types of chronic kidney disease (CKD). However, the noninvasive detection of renal fibrosis remains a challenge. METHODS: We collected urine samples from 154 biopsy-proven IgA nephropathy (IgAN) patients and 61 healthy controls. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Yuhan, Wang, Yuwei, Liu, Yinhua, Zhu, Xinjian, Zhang, Guifa, Wang, Sufen, Chen, Xiaomei, Liu, Daoqin, Fu, Cong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710774/ https://www.ncbi.nlm.nih.gov/pubmed/31485275 http://dx.doi.org/10.1155/2019/2424751

Ejemplares similares

IgAN Genetic Risk Score in the Clinical Setting
por: Schena, Francesco Paolo, et al.
Publicado: (2020)

New directions in the pathogenesis of primary erythrocytosis in IgAN
por: Schena, Francesco Paolo, et al.
Publicado: (2022)

Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN)
por: De Angelis, Maria, et al.
Publicado: (2014)

Proteomic signature of tubulointerstitial tissue predicts prognosis in IgAN
por: Paunas, Flavia Teodora Ioana, et al.
Publicado: (2022)

Identification of key cuproptosis-related genes and their targets in patients with IgAN
por: Lin, Huagang, et al.
Publicado: (2022)

The ratio of urinary TREM-1/TREM-2 mRNA expression in chronic kidney disease and renal fibrosis
por: Cao, Yuhan, et al.
Publicado: (2021)

The Role of Renal Macrophage, AIM, and TGF-β1 Expression in Renal Fibrosis Progression in IgAN Patients
por: Yang, Min, et al.
Publicado: (2021)

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
por: Rizk, Dana V., et al.
Publicado: (2023)

Chemokine (C–C motif) receptor 2 is associated with the pathological grade and inflammatory response in IgAN children
por: Shen, Yanjie, et al.
Publicado: (2022)

APOC1 exacerbates renal fibrosis through the activation of the NF-κB signaling pathway in IgAN
por: Yu, Kuipeng, et al.
Publicado: (2023)

Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)
por: Schimpf, Judith Isabel, et al.
Publicado: (2018)

Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients
por: Zand, Ladan, et al.
Publicado: (2023)

Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis
por: Ebbestad, Robin, et al.
Publicado: (2022)

The solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN disease
por: Hui, Gar Kay, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
por: Ramjee, Lauren, et al.
Publicado: (2023)

TFRC–RNA interactions show the regulation of gene expression and alternative splicing associated with IgAN in human renal tubule mesangial cells
por: Li, Jian-Si, et al.
Publicado: (2023)

scIGANs: single-cell RNA-seq imputation using generative adversarial networks
por: Xu, Yungang, et al.
Publicado: (2020)

The molecular mechanisms of inflammation and scarring in the kidneys of immunoglobulin A nephropathy: Gene involvement in the mechanisms of inflammation and scarring in kidney biopsy of IgAN patients
por: Schena, Francesco Paolo, et al.
Publicado: (2021)

Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin-mediated autophagy
por: Lin, Fan, et al.
Publicado: (2021)

Rheb and mammalian target of rapamycin in mitochondrial homoeostasis
por: Groenewoud, Marlous J., et al.
Publicado: (2013)

The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes
por: Lisi, Lucia, et al.
Publicado: (2011)

Mammalian Target of Rapamycin: Hitting the Bull's-Eye for Neurological Disorders
por: Chong, Zhao Zhong, et al.
Publicado: (2010)

Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells
por: ZHANG, DEJUN, et al.
Publicado: (2014)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
por: Ghosh, Hiyaa Singhee, et al.
Publicado: (2010)

Mammalian target of rapamycin signaling in diabetic cardiovascular disease
por: Chong, Zhao Zhong, et al.
Publicado: (2012)

Driving neural regeneration through the mammalian target of rapamycin
por: Maiese, Kenneth
Publicado: (2014)

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin
por: Khadir, Fatemeh, et al.
Publicado: (2018)

Autism Spectrum Disorder and Mammalian Target of Rapamycin System
por: Posar, Annio, et al.
Publicado: (2020)

Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling
por: Yan, Junfang, et al.
Publicado: (2021)

Isoleucine Regulates the Synthesis of Pancreatic Enzymes via the Activation of mRNA Expression and Phosphorylation in the Mammalian Target of Rapamycin Signalling Pathways in Pancreatic Tissues
por: Cao, Yangchun, et al.
Publicado: (2019)

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
por: Jin, Hong-Guang, et al.
Publicado: (2018)

Recent advances of the mammalian target of rapamycin signaling in mesenchymal stem cells
por: Cai, Huarui, et al.
Publicado: (2022)

Mammalian Tribbles Homologs at the Crossroads of Endoplasmic Reticulum Stress and Mammalian Target of Rapamycin Pathways
por: Cunard, Robyn
Publicado: (2013)

Destabilization of TNF-α mRNA by Rapamycin
por: Park, Jong-Woo, et al.
Publicado: (2012)

Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer
por: Pan, Yanhong, et al.
Publicado: (2017)

Crosstalk between Edc4 and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in mRNA Decapping
por: Rahman, Hazir, et al.
Publicado: (2014)

Mammalian target of rapamycin and head and neck squamous cell carcinoma
por: Liao, Yu-Min, et al.
Publicado: (2011)

New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma
por: Agulnik, Mark
Publicado: (2012)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8thu4cq4hd854tc7cs34tc22f0